-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-507803-76-00
10
2024-09-26
Peripheral T-Cell Lymphoma
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-508158-24-00
4
2024-06-25
Moderately to Severely Active Crohn’s Disease
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2022-502193-16-00
5
2023-11-14
Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
-
2022-502357-34-00
5
2023-09-27
Extensive Stage Small Cell Lung Cancer
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-508879-36-00
5
2022-04-28
Pruritus
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-522105-38-00
5
2026-02-02
Chronic Hepatitis Delta Infection
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-515973-82-00
4
2025-06-23
ACPA-Positive Rheumatoid Arthritis
-
2024-516609-22-00
5
2025-04-15
Primary Sjögren’s Disease
-
2023-509239-19-00
5
2025-04-03
Active Psoriatic Arthritis
-
2024-516213-20-00
5
2025-03-25
Psoriatic arthritis
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2023-503714-77-00
4
2024-10-01
Advanced Non-Small Cell Lung Cancer